Bispecific antibodies do something a single antibody can’t: bind two targets within one molecule. Enough of them have reached the clinic that the format is now an established drug class, and more programs start every year.
The concept is straightforward. However, making a bispecific that works as a drug is where some programs get stuck.
The hard part is execution. A bispecific has to assemble correctly, express at a yield you can manufacture, and hold together through the path to the clinic. The commercially available antibody platforms solve (or attempt to solve) those problems in very different ways. Those differences matter more than any vendor website makes clear.
This guide is for anyone deciding how to make a bispecific, or comparing one discovery platform against another. I’ll briefly cover what a bispecific actually is, the assembly problem every platform has to solve, how the molecules get discovered, and the specific numbers worth asking a provider for before you commit.
Just to make sure we’re on the same page, a regular antibody has two identical arms, and both grab the same target. A bispecific antibody has two different arms, so one molecule can bind two targets at once.
That does things a single antibody cannot: pull an immune cell up against a tumor cell, block two signals at the same time, or grab two spots on one target to hold on more tightly.
The idea is decades old. Making bispecifics that behave like real drugs is the part that stayed hard. Most of the difficulty comes down to one thing: assembly.
Bispecific antibodies have emerged as one of the most promising therapeutic modalities, validated both clinically and commercially, with the ability to unlock new mechanisms of action. This is exemplified in that the development of this class of biological therapeutic is growing at an accelerated pace compared to more standard monospecific approaches,” said Emily M. Leproust, CEO and co-founder of Twist Bioscience.
An antibody is built from four chains, two heavy and two light, and each arm is a heavy chain paired with its matching light chain. In a normal antibody, the two arms are identical, so there is only one correct way for the chains to come together.
In a bispecific, the two arms are different, and now the chains can mix and match. A heavy chain from one arm can grab the light chain meant for the other. Do that across a batch and you get a mess of mispaired, non-functional molecules instead of the one you designed. Add more variety and the number of wrong combinations climbs fast.
Platforms deal with this in different ways, and the choice has consequences.
Some give up the natural antibody shape. They fuse fragments together or build scaffolds that are not quite an IgG. That controls assembly, but you lose what a real antibody gives you for free: a long half-life in the body and a manufacturing process that facilities already know how to run.
Others keep the IgG shape but force every arm onto a single shared, or “common,” light chain. That removes the mispairing question and narrows your options at the same time. You can only use binders that happen to work with that one light chain, so you may have to leave your best antibody on the table.
The third route keeps a real IgG and engineers the parts of the antibody that do not touch the target, so the correct chains pair on their own while the binding regions stay untouched. That is the approach behind the Invenra B-Body platform, and the section below on the platform explains how it works.